Coronavirus fusion peptide plays more invasive role in infection than previously thought

NewsGuard 100/100 Score

Although the COVID-19 pandemic was the first time most of humanity learned of the now infamous disease, the family of coronaviruses was first identified in the mid-1960s. In a new study, molecular biologist Steven Van Doren, a scientist in the University of Missouri College of Agriculture, Food and Natural Resources, has uncovered unexpected actions of a key player in how the coronavirus infects its target -; a discovery that could guide further vaccine development.

Funded by a National Science Foundation (NSF) grant, Van Doren and his team studied the fusion peptide, an important feature of the spike protein that serves to bind the virus with the human cell, an essential step in the course of infection. In this study, they found that the fusion peptide plays a more invasive role in fusing the virus to the cell than previously thought, which is significant in understanding how infection occurs.

The fusion peptide is the most preserved part of the whole viral spike. Throughout the evolution of this virus, the fusion peptide endured despite all the mutations and variants that we kept on hearing about in the news. The fusion peptide never changed much and stayed a constant feature on the virus spike because it's too critically important for infection for it to be modified."

Van Doren, professor of biochemistry

The fusion peptide on the SARS-CoV-2 spike (pictured here) plays a key role in virus/cell attachment.

This research is interesting to compare to a recent study that surveyed asymptomatic patients who were infected by the coronavirus because they had developed a defense mechanism known as broadly neutralizing antibodies. Van Doren's research on the functionality of the fusion peptide's ability to puncture a cell membrane could further inform why the fusion peptide may be an important target for vaccine development capable of fighting all types of coronavirus infections.

Another potential application of this research could be to create a novel strategy to penetrate cells.

"There may be many strategies for crossing membranes, but it's conceivable that the fusion peptide work could help further development of more ways to cross cellular membranes, which could be useful to deliver therapeutics through cell membranes," Van Doren said.

Further, this research broadens understanding of protein insertion in membranes, which has broader relevance to the scientific community.

"I love what protein molecules look like and what they can do," Van Doren said. "I got fascinated by the science when I was still a teenager, and it's intriguing to me the things they can do, so studying how proteins work has been something that has stuck with me for decades now -; I'd say going on almost 40 years."

The study "SARS-CoV-2 Fusion Peptide Sculpting of a Membrane with Insertion of Charged and Polar Groups" was published in Structure. Co-investigators include Benjamin S. Scott and Rama K. Koppisetti.

Source:
Journal reference:

Van Doren, S.R., et al. (2023) SARS-CoV-2 fusion peptide sculpting of a membrane with insertion of charged and polar groups. Structure. doi.org/10.1016/j.str.2023.07.015.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows potential for universal flu vaccine with broad antibody response